ヒトのノラドレナリントランスポーターの再吸収と抑制の分子基礎
Jiaxin Tan1, Yuan Xiao1, Fang Kong1
1Beijing Frontier Research Center for Biological Structure, State Key Laboratory of Membrane Biology, Tsinghua-Peking Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.
Nature
|July 24, 2024
まとめ
研究者らは,ノラドレナリンとドーパミンのような基質が結合する方法を詳細に説明する人間のノラドレナリントランスポーター (NET) 構造を明らかにした. この研究では4つの抗うつ薬が NET機能を阻害し そのメカニズムの洞察力も提供しています
科学分野:
- 神経科学
- 構造生物学
- 薬理学について
背景:
- ノルアドレナリン (ノレピネフリン) は多くの脳細胞タイプに影響を与えます.
- ノラドレナリントランスポーター (NET) は,シナプス裂け目からノラドレナリンをクリアするのに不可欠です.
- NETの構造と機能を理解することは 効果的な抗うつ薬の開発の鍵です
研究 の 目的:
- 人間のNETの冷凍電子顕微鏡 (cryo-EM) 構造を決定する.
- 基質と抗うつ薬のNETへの結合メカニズムを解明する.
- 抗うつ薬によるNET阻害の機能的およびメカニズム的詳細を明らかにする.
主な方法:
- 低温電子顕微鏡 (cryo-EM) を使用して,人間のNETの高解像度構造を取得しました.
- 構造はアポ状態およびサブストラット (ノラドレナリン,ドーパミン) と抗うつ薬 (アトモクセチン,デシプラミン,ブプロピオン,エシタロプラム) との複合で決定された.
- 構造データは生化学分析で補完された.
主要な成果:
- 人間のNETの冷凍-EM構造は2.5〜3.5 Åの解像度で解像しました.
- ノルアドレナリンとドーパミンは,中央部位 (S1) と新たに特定されたアロステリック部位 (S2) で類似した結合方式を共有しています.
- 4つの抗うつ剤はS1部位に結合し,異なる形状によって基質輸送を阻害する.特定の条件下でナトリウム結合部位にカリウムイオンが観察された.
結論:
- この研究は,ヒトのNETの基板認識と輸送メカニズムに関する詳細な構造的洞察を提供します.
- 抗うつ薬の固有の結合方式は,NETを阻害する作用メカニズムを明らかにする.
- これらの発見は,NETの機能と抗うつ薬の薬理学に関する理解を深めています.
関連する概念動画
Drugs Affecting Neurotransmitter Release or Uptake
1.0K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.0K
Adrenergic Neurons: Neurotransmission
3.6K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
Synthesis: Catecholamine synthesis requires tyrosine, which...
3.6K
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Adrenergic Agonists: Indirect-Acting Agents
1.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K
Adrenergic Receptors: ɑ Subtype
1.5K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.5K
Adrenergic Receptors: β Subtype
1.6K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.6K


